LLY

1,083.86

-1.74%↓

JNJ

223.31

-0.83%↓

ABBV

213.03

-2.26%↓

UNH

378.2

-0.12%↓

MRK

115.57

-2.55%↓

LLY

1,083.86

-1.74%↓

JNJ

223.31

-0.83%↓

ABBV

213.03

-2.26%↓

UNH

378.2

-0.12%↓

MRK

115.57

-2.55%↓

LLY

1,083.86

-1.74%↓

JNJ

223.31

-0.83%↓

ABBV

213.03

-2.26%↓

UNH

378.2

-0.12%↓

MRK

115.57

-2.55%↓

LLY

1,083.86

-1.74%↓

JNJ

223.31

-0.83%↓

ABBV

213.03

-2.26%↓

UNH

378.2

-0.12%↓

MRK

115.57

-2.55%↓

LLY

1,083.86

-1.74%↓

JNJ

223.31

-0.83%↓

ABBV

213.03

-2.26%↓

UNH

378.2

-0.12%↓

MRK

115.57

-2.55%↓

Strona główna・Stock List・AnaptysBio Inc

AnaptysBio Inc

Open

SectorHealthcare

52.58 -5.38

Buy Sell

Overview

Share price change

24h

Current

Min

52.32

Max

55.57

Key metrics
By Trading Economics
Income	-102M -53M
Sales	-83M 26M
EPS	-1.843
Profit margin	-206.934
Employees	104
EBITDA	-102M -34M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+44.6% upside

Dividends
By Dow Jones
Next Earnings	4 sie 2026

Market Stats
By TradingEconomics
Market Cap	-272M 1.7B
Previous open	57.96
Previous close	52.58

News Sentiment

By Acuity

100%

320 / 344 Ranking in Healthcare

AnaptysBio Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

31 maj 2026, 23:44 UTC

Market Talk

Nikkei May Remain Rangebound Amid Middle East Uncertainty -- Market Talk

31 maj 2026, 23:36 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

31 maj 2026, 23:36 UTC

Market Talk

Oil Rises Amid Few Signs of Strait of Hormuz's Reopening -- Market Talk

31 maj 2026, 23:36 UTC

Market Talk

Watch for Data-Center Investment in Australia's 1Q GDP Print -- Market Talk

31 maj 2026, 22:54 UTC

Acquisitions, Mergers, Takeovers

Berkshire Hathaway to Buy Homebuilder Taylor Morrison for $6.8 Billion -- WSJ

29 maj 2026, 23:08 UTC

Acquisitions, Mergers, Takeovers

Family Offices Bypass Private Equity and Go Direct -- Barrons.com

29 maj 2026, 23:06 UTC

Acquisitions, Mergers, Takeovers

After a Series of Sales, Hims Director Buys Company Shares -- Barrons.com

29 maj 2026, 20:53 UTC

Earnings

Oil Declines Lift Stocks to Fresh Records -- WSJ

29 maj 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

29 maj 2026, 20:33 UTC

Market Talk

Canada Meets Only One of Three Criteria To Declare Recession -- Market Talk

29 maj 2026, 20:11 UTC

Earnings

Okta Stock Soars. What's Stealing the Show From Earnings. -- Barrons.com

29 maj 2026, 19:47 UTC

Earnings

These Were the Best and Worst S&P 500 Stocks in May -- Barrons.com

29 maj 2026, 19:36 UTC

Market Talk

U.S. Natural Gas Futures End Month With Gains -- Market Talk

29 maj 2026, 19:34 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

29 maj 2026, 19:34 UTC

Market Talk

Over Half of Canadian Industries Growing, Undermining Recession Talk -- Market Talk

29 maj 2026, 19:22 UTC

Market Talk

Oil Falls as U.S., Iran Expected to Reach Agreement -- Market Talk

29 maj 2026, 19:05 UTC

Acquisitions, Mergers, Takeovers

Universal Music Group Rejects $65 Billion Takeover Bid From Bill Ackman's Pershing Square -- Barrons.com

29 maj 2026, 18:19 UTC

Market Talk

Canada Technical Recession Chatter Rife But Per-Capita GDP Was Up -- Market Talk

29 maj 2026, 18:12 UTC

Acquisitions, Mergers, Takeovers

Universal Music Group Rejects $65 Billion Buyout Offer From Bill Ackman -- WSJ

29 maj 2026, 18:11 UTC

Market Talk

Canada Households Reaching Limit at Keeping Spending in Positive Territory -- Market Talk

29 maj 2026, 18:10 UTC

Market Talk

As BTC Long-Term Holders Rise, Short-Term Holders Flee -- Market Talk

29 maj 2026, 17:55 UTC

Earnings

Okta Stock Soars. What's Stealing the Show From Earnings. -- Barrons.com

29 maj 2026, 17:55 UTC

Market Talk

NEAR Protocol Nearly Doubles in May -- Market Talk

29 maj 2026, 17:38 UTC

Market Talk

U.S. Oil Rig Count Rises for Fifth Straight Week -- Market Talk

29 maj 2026, 17:00 UTC

Earnings

Okta Stock Soars After Earnings. Results Aren't the Real Catalyst. -- Barrons.com

29 maj 2026, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

29 maj 2026, 16:20 UTC

Market Talk

Health Care Roundup: Market Talk

29 maj 2026, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

29 maj 2026, 16:02 UTC

Market Talk

Gold Extend Gains as Investors Await U.S.-Iran Deal News -- Market Talk

29 maj 2026, 15:55 UTC

Market Talk

Global Equities Roundup: Market Talk

Peer Comparison

Price change

AnaptysBio Inc Forecast

Price Target

By TipRanks

44.6% upside

12 Months Forecast

Average 80.5 USD 44.6%

High 140 USD

Low 50 USD

Based on 11 Wall Street analysts offering 12 month price targets forAnaptysBio Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

11 ratings

Buy

Hold

Sell

Based on 11 analysts giving stock ratings to AnaptysBio Inc - Dist in the past 3 months.

Sentiment

By Acuity

320 / 344 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About AnaptysBio Inc

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.